The aim of this study is to explore the possibility to predict PFS and OS in NSCLC patients, including patients with EGFRex20ins, based on pre- and on-treatment tumor growth dynamics. In addition, clinical characteristics, lines of therapy, and RECIST 1.1 – based response rates (ORR) under various standards of care are characterized for patients harboring EGFRex20ins or other driver mutations and patients without driver mutations.
LChanges to the permit: change of processors
Issuer of the original permit: Findata